Sepsis: protecting the glycocalyx remains a largely preclinical avenue

A target linked to vascular damage in sepsis

The endothelial glycocalyx is a layer on the inner surface of blood vessels. Its degradation during sepsis contributes to vascular dysfunction, increased permeability, inflammation and thrombosis in the microcirculation. These disturbances contribute to organ failure.

Preserving this structure is therefore a biologically plausible approach. However, this does not demonstrate that a treatment acting on the glycocalyx improves patient outcomes. According to the abstract, therapies specifically targeting this structure are not currently part of standard sepsis care.

Very different interventions, few human studies

The review includes 21 studies: 17 animal studies and four human studies. The interventions examined include ascorbic acid, sulodexide, doxycycline, heparin-based treatments, antithrombin and therapeutic plasma exchange.

This diversity matters: the abstract does not allow these approaches to be ranked or the same level of evidence to be assigned to each. The inclusion of vitamin C in this list does not demonstrate a benefit from supplementation against sepsis.

Biological signals, not an established clinical benefit

The studies assessed circulating markers of glycocalyx degradation, including syndecan-1, heparan sulfate and hyaluronan. Some also used measurements of the microcirculation or examined the structure using microscopy.

Several interventions reduced glycocalyx degradation or improved measures of vascular barrier integrity and microvascular function. In some experimental models, its structure was preserved or restored. These observations must not be equated with a demonstrated reduction in organ failure or mortality in humans.

What this review tells us

The glycocalyx warrants investigation as a therapeutic target, but the authors call for well-designed clinical studies and standardized outcome measures. The abstract provides neither a numerical estimate of clinical benefit nor detailed safety data that could guide treatment choices.

What we can take away

This review supports an avenue of research into sepsis, not a recommendation for supplementation or treatment targeting the glycocalyx.